Keyword Analysis & Research: isarna


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
isarna0.170.18956256

Keyword Research: People who searched isarna also searched

Keyword CPC PCC Volume Score
isarna0.90.4795484
isarna therapeutics1.990.4316211
isarnauten1.951521811
isarna therapeutics gmbh1.760.4375631
isarna holding gmbh1.510.6528323
isarna custom machining inc0.020.1472344
isarnauten maurer gmbh0.170.2895040
isarna custom machining beamsville1.050.327404

Search Results related to isarna on Search Engine

  • Isarna Therapeutics – Leading Expertise in TGF-ß Biology and …

    isarna-therapeutics.com

    https://isarna-therapeutics.com/

    WebIsarna Therapeutics was built on profound knowledge in antisense oligonucleotide design and therapeutic development of this innovative compound class. Today, Isarna is developing a portfolio of antisense therapies targeting an emerging therapeutic field in human biology - TGF-β signaling.

    DA: 14 PA: 84 MOZ Rank: 39

  • The Company – Isarna Therapeutics

    isarna-therapeutics.com

    https://isarna-therapeutics.com/the-company/

    WebAbout Us. Isarna Therapeutics was built on profound knowledge in antisense oligonucleotide design and therapeutic development of this innovative compound class. Today, Isarna is developing a portfolio of antisense therapies targeting an emerging therapeutic field in human biology - TGF-B signaling.

    DA: 82 PA: 22 MOZ Rank: 76

  • Pipeline – Isarna Therapeutics

    isarna-therapeutics.com

    https://isarna-therapeutics.com/pipeline/

    WebIsarna has established a broad portfolio of next-generation first- and best-in-class antisense oligonucleotides blocking three key TGF-β variants with therapeutic potential across a range of indications.

    DA: 44 PA: 28 MOZ Rank: 61

  • Isarna Therapeutics Announces First Patient Enrolled in …

    businesswire.com

    https://www.businesswire.com/news/home/20211130005080/en/Isarna-Therapeutics-Announces-First-Patient-Enrolled-in-International-Phase-2a-Clinical-Study-in-Ophthalmology-Indications-Wet-AMD-and-DME

    WebNov 30, 2021 · Isarna Therapeutics Announces First Patient Enrolled in International Phase 2a Clinical Study in Ophthalmology Indications Wet AMD and DME. November 30, 2021 05:00 AM Eastern Standard Time....

    DA: 56 PA: 89 MOZ Rank: 53

  • Isarna Therapeutics Presents Update from Phase 2 BETTER …

    businesswire.com

    https://www.businesswire.com/news/home/20220831005077/en/Isarna-Therapeutics-Presents-Update-from-Phase-2-BETTER-Clinical-Study-in-Wet-AMD-and-DME-at-the-EURETINA-Meeting

    WebAug 31, 2022 · Isarna has developed ISTH0036 to target the transforming growth factor-beta (TGF-β), a protein which is chronically elevated in ophthalmic, fibrotic, immunologic, and cancerous diseases.

    DA: 52 PA: 63 MOZ Rank: 38

  • Looking beyond the standard of care for eye diseases - Nature

    nature.com

    https://www.nature.com/articles/d43747-021-00054-6

    WebIsarna Therapeutics’ antisense therapy targeting transforming growth factor beta 2, ISTH0036, is about to enter phase 2 clinical development for two retinal diseases: wet …

    DA: 2 PA: 45 MOZ Rank: 91

  • Isarna Therapeutics GmbH | LinkedIn

    linkedin.com

    https://www.linkedin.com/company/isarna-therapeutics-gmbh

    WebAbout us. Isarna Therapeutics is a clinical stage biotech company, headquartered in Munich, Germany. Isarna develops ISTH0036, a next-generation antisense to block TGF-beta 2 production, a key...

    DA: 18 PA: 100 MOZ Rank: 55

  • Isarna Therapeutics Appoints Claus Schalper as CEO

    businesswire.com

    https://www.businesswire.com/news/home/20210930005043/en/Isarna-Therapeutics-Appoints-Claus-Schalper-as-CEO

    WebSeptember 30, 2021 05:00 AM Eastern Daylight Time. MUNICH-- ( BUSINESS WIRE )-- Isarna Therapeutics today announced the appointment of Claus Schalper as Chief Executive Officer. Mr. Schalper...

    DA: 53 PA: 24 MOZ Rank: 18

  • Isarna Therapeutics Presents Positive Clinical Data For ... - BioSpace

    biospace.com

    https://www.biospace.com/article/releases/isarna-therapeutics-presents-positive-clinical-data-for-isth0036-in-advanced-glaucoma-and-preclinical-data-supportive-of-amd-dme-potential-at-arvo-201/

    WebMay 15, 2017 · Isarna Therapeutics has an unmatched commitment to developing selective TGF-ß inhibitors to fight cancer and to effectively treat ophthalmic and fibrotic diseases. We are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.

    DA: 97 PA: 12 MOZ Rank: 8

  • Isarna Therapeutics Presents Update From Phase 2 BETTER

    eyewire.news

    https://eyewire.news/news/isarna-therapeutics-presents-update-from-phase-2-better-clinical-study-in-wet-amd-and-dme-at-the-euretina-meeting

    WebAug 31, 2022 · Isarna has developed ISTH0036 to target the transforming growth factor-beta (TGF-β), a protein which is chronically elevated in ophthalmic, fibrotic, immunologic, and cancerous diseases. ISTH0036 suppresses TGF-β protein production via well-studied antisense mechanisms. Visit Eyewire News to see the latest in eye care news stories. …

    DA: 86 PA: 95 MOZ Rank: 74


© 2021. All rights reserved